SCHEMBL8738665

SCHEMBL8738665

CN1CCC(N(C)C(=O)c2ccc(Oc3ccccc3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.58
JAK1 P23458 1/20 0.58
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
RHEB Q15382 1/20 0.52
MCHR1 Q99705 1/20 0.52
CCR5 P51681 2/20 0.51
KDM4E B2RXH2 1/20 0.50
PKM P14618 1/20 0.50
USP30 Q70CQ3 2/20 0.49
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47
CCR3 P51677 1/20 0.47
POLB P06746 1/20 0.47
NPY5R Q15761 1/20 0.47
SCN1A P35498 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
HTR2A P28223 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6120915 0.88 USP30 (0.53) JAK2JAK1MEN1KMT2AMCHR1
SCHEMBL3329900 0.87 CCR5 (0.55) JAK2JAK1MEN1KMT2AMCHR1
SCHEMBL3454773 0.85 MEN1 (0.70) MEN1KMT2APOLB
SCHEMBL15088420 0.85 MCHR1 (0.67) JAK2JAK1KMT2AMCHR1HTR2A
SCHEMBL8738173 0.83 SLC6A4 (0.59) MEN1KMT2APOLBNPY5R
SCHEMBL15388238 0.82 USP30 (0.70) MEN1KMT2AUSP30
SCHEMBL12082859 0.80 PDK2 (0.61) JAK2JAK1MCHR1CCR5HRH3
SCHEMBL25498560 0.80 LMNA (0.65) MCHR1CCR5USP30ADORA2AADORA1
SCHEMBL3333340 0.79 HRH3 (0.61) RHEBMCHR1CCR5USP30HRH3
SCHEMBL1164100 0.79 MCHR1 (0.50) MCHR1CCR5USP30ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310379-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-11-21 US disclosed
WO-2012068589-A2 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310379-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 JAK2 4240/4885JAK1 3553/4885MEN1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.